Track ELVN and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Enliven Therapeutics Inc.
6200 Lookout Road, Boulder, CO, United States, 80301
IPO
2020
Employees
61
Industry
Biotechnology
Sector
Healthcare
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q1 202610-10
0
Q4 20258-8
0
Q3 20252-2
0
3-quarter cumulative
20 sells0 buys
Analyst Ratings
1 analysts covering
Buy100%recommend buy
Buy
1
Hold
0
Sell
0